University of California, Davis
Division of University of California
Latest From University of California, Davis
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.
There is a need for assays to help guide therapy with the growing number of anticoagulant drugs on the market, but without clearer FDA guidelines development will be a challenge, companies and labs tell the agency.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.